M16-077 Elezanumab Ph 2a POC SCI ELASCI
ClinicalTrials.gov NCT04295538
Research payments
$22,166
Through program year 2024, $22,166 in research payments was reported against M16-077 Elezanumab Ph 2a POC SCI ELASCI, across 21 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT04295538
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $22,166 | 21 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Mohammed Khan Oradell, NJ Named on 1 payment
- Brian Cameron Richmond, VA Named on 1 payment
- Nasim Ahmed Neptune, NJ Named on 1 payment
- Saman Shabani Milwaukee, WI Named on 1 payment
- Aruna Ganju Chicago, IL Named on 1 payment
- Aaron Richman Boston, MA Named on 1 payment
- Christine Sang Boston, MA Named on 1 payment
- James Schuster Philadelphia, PA Named on 1 payment
- Won Ryu Portland, OR Named on 1 payment
- Chun Po Yen Charlottesville, VA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.